Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Indianapolis, Indiana 46203


The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds. Whether the two or three drugs listed above when given in combination can help patients with metastatic breast cancer. How long the treatment will stop the growth of the cancer.


Inclusion Criteria: 1. Diagnosis of metastatic breast cancer 2. Able to visit the doctor's office at least every 14 days during the actual treatment 3. Able to care for yourself, even if you cannot work or participate in other normal activities 4. Your blood results must be adequate for therapy. 5. If you are a female of childbearing potential and test negative for pregnancy, use a reliable method of birth control during and for three months following the last dose of study drug. Exclusion Criteria: 1. Have received gemcitabine, paraplatin, or trastuzumab for your cancer. 2. Be pregnant or breastfeeding 3. Have cancer to the brain and has not been treated 4. Have another active cancer besides breast cancer 5. Have received stem cell or bone marrow transplant for hematologic (blood type) cancer



Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company

Backup Contact:


Location Contact:

Indianapolis, Indiana 46203
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.